Current State of the Peptide Market and Where it's Headed in Telehealth

The peptide therapeutics market is one of the fastest-growing areas in biopharma, so if it’s not currently on your radar, it should be. What was once viewed as a niche segment of drug development is today a high-growth solution attracting longevity, aesthetics, and wellness markets. 

We’ll break down the current market data and explore what you can expect from the peptide market in 2026 and beyond. 

Current State of the Peptide Market in 2026 and Where It’s Headed

In 2025, the global peptide therapeutics market was estimated at $140.86 billion, and is anticipated to hit $163.98 billion in 2026. By 2033, the market is projected to reach $294.58 billion, growing at a CAGR of 8.73% from 2026 to 2033. Essentially, the market will almost double in under a decade. 

Other Key Highlights 

The market also isn’t monolithic. Digging deeper into the data reveals where dominance lies across key market segments. 

Grand View Research 

What’s Driving Growth in the Peptide Therapeutics Market?

The numbers make it clear that peptides are trending up, but understanding the peptide market opportunity in 2026 requires looking beyond the figures. The other half of the equation is understanding why growth is happening, so you can assess whether this is a long-term shift or a short-lived market spike. 

Here’s what’s causing momentum. 

GLP-1 Therapies Validated the Category at Scale

One of the primary reasons people are looking at peptides is the hormone glucagon-like peptide-1 (GLP-1). It’s proven highly effective for type 2 diabetes and weight loss and is being studied for other applications, including cardiovascular events and kidney disease. 

The GLP-1 market was $66.38 billion in 2025, and is expected to reach $185.32 billion by 2032. This alone has exploded the peptide market interest.

Peptides Are Expanding Across Therapeutic Areas

GLP-1s may have opened the door, but peptide applications are expanding. In addition to treating metabolic disorders, peptides are also making waves in the following areas: 

Additionally, the global peptide cosmetic market, which includes serums, moisturizers, face creams, and eye treatments, was valued at $2.62 billion in 2025. It’s projected to reach $8.28 billion by 2035, growing at a CAGR of 12.3%. 

As one study noted, they have unique biochemical properties, are versatile across therapeutic applications, and are “shaping the future of healthcare through their unparalleled therapeutic promise.” 

Consumer Awareness is Growing

Consumer search interest in peptides has surged alongside market growth. GLP-1s didn’t just validate peptides clinically; they introduced their potential to the mainstream. Social media and influencer education have accelerated awareness. According to Google Trends, between April 2025 and April 2026 in the United States:

• "Cost of peptide therapy" searches increased by +300%

• "peptides" are up 80% and "what is peptides" up by 70%

• "Peptide therapy cost" increased by +100%

Consumer Search Interest

This all signals that consumer awareness is rapidly converting into active consideration, and that demand will only continue to build. 

Oral Delivery is Becoming Feasible 

Peptides are particularly sensitive to digestive enzymes because they break down in stomach acid and are poorly absorbed through the gut lining, reducing how much reaches a person’s bloodstream. For this reason, they've typically not been administered orally, but that's changing. 

According to Grand View Research, oral peptide delivery is advancing due to improved formulations and absorption-enhancing technologies.

This change matters because oral treatment could: 

• Improve outcomes 

• Make treatment more accessible

• Increase treatment adherence rates 

• Expand the patient populations eligible for peptide-based programs 

• Remove the friction of injection-dependent protocols by making treatment less intimidating for patients who are uncomfortable with self-injection

The Manufacturing Infrastructure is Scaling with Demand

Peptide market growth is not just showing up in the pipeline. It is showing up in manufacturing.

Companies across the market are expanding peptide production capacity and investing in larger-scale infrastructure to meet rising demand. CordenPharma has announced major peptide capacity expansions in the U.S. and Europe, Cambrex has tied new U.S. investment to growth in peptide therapeutics, and Lupin Manufacturing Solutions recently expanded its peptide manufacturing capabilities. That kind of investment signals a market that is maturing for the long term, not peaking in the moment.

AI Is Expanding What’s Possible in Peptide Discovery

AI is becoming an important tool in peptide development. The research points to AI-driven computational design as one of several advances helping researchers improve peptide discovery and explore targets that were previously difficult to treat.

For market watchers, that signals a more efficient innovation engine — but AI is only part of the story. Growth in peptide therapeutics is also being shaped by broader advances in synthesis, delivery, and clinical application.

Peptide Market Opportunity in 2026

The data shared here makes one thing clear: the peptides therapeutic market isn’t slowing down. So, the discussions surrounding peptides aren't whether there’s an opportunity, but whether your organization is prepared to act on it and where things stand on the regulatory front. 

Are You Prepared? 

Organizations best positioned to capitalize are: 

• Designing care pathways for emerging oral formulations

• Building infrastructure to scale peptide-based care efficiently

• Strengthening provider network strategy ahead of rising demand

• Monitoring the FDA landscape and adapting operations quickly 

What is The Current Regulatory Peptide Landscape?

As of now, the FDA is actively discussing oversight around compounded peptide formulations, and the regulatory peptide landscape is evolving quickly. Discussion around the potential reclassification of 14 FDA Category 2 peptides is also in motion. Understanding where the regulatory lines are drawn and how they might shift is crucial before entering the space. 

Key things to know right now: 

• The FDA has not issued formal reclassification guidance.

• Category 2 peptides cannot be used in compounding unless the FDA authorizes their use through rulemaking 

• The regulatory framework governing bulk substances is unchanged.

• Healthcare organizations are still monitoring changes in FDA guidance.

Be Ready for the Peptide Therapeutics Market 

The evolving peptide market is still in its early stages, and market data suggest it’s going to grow fast. Those waiting to see how it fully matures will be playing catch-up. Organizations that invest in a proper digital health infrastructure, expansive provider and pharmacy network, and scalable clinical operations are the ones that will win. 

OpenLoop’s end-to-end, peptide-ready, white-label infrastructure is already built and ready to plug into your organization. You build and own your brand, we handle everything else behind the scenes. Don’t fall behind if peptide regulations change, be ready for it.

OpenLoop’s infrastructure provides:

• White-label virtual care platform

• Nationwide pharmacy and lab networks

• Demand-ready protocols and workflows

• 24/7/365 patient support 

• 50-state clinician coverage and PC network

• Built-in regulatory and compliance frameworks

• And more

Want to be peptide-ready? Contact us today! 

*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.